Regen BioPharma, Inc. (RGBP)
OTCMKTS · Delayed Price · Currency is USD
0.0010
-0.0001 (-9.09%)
Mar 5, 2026, 9:52 AM EST

Regen BioPharma Balance Sheet

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Cash & Equivalents
00.0700.120.050.73
Cash & Short-Term Investments
00.0700.120.050.73
Cash Growth
3291.11%9614.39%-99.41%136.38%-92.96%-
Accounts Receivable
0.230.20.09-0.250.21
Other Receivables
-----0
Receivables
0.230.20.09-0.250.22
Prepaid Expenses
000.050.010.030.05
Total Current Assets
0.240.270.140.130.340.99
Long-Term Investments
--0.020.220.220.22
Total Assets
0.240.270.160.350.561.21
Accounts Payable
0.0100.030.030.030.09
Accrued Expenses
1.851.841.661.6422.27
Short-Term Debt
0.130.190.290.101.43
Current Portion of Long-Term Debt
0.951.010.50.511.272.15
Current Unearned Revenue
1.311.341.471.611.721.84
Other Current Liabilities
2.562.181.431.423.576.91
Total Current Liabilities
6.816.565.385.318.614.7
Long-Term Debt
---0.15--
Total Liabilities
6.816.565.385.468.614.7
Common Stock
0.010000.50.44
Additional Paid-In Capital
16.315.6315.414.6412.329.38
Retained Earnings
-22.66-21.69-20.42-19.75-20.91-23.35
Comprehensive Income & Other
-0.22-0.22-0.2-0--
Total Common Equity
-6.57-6.28-5.22-5.1-8.08-13.53
Shareholders' Equity
-6.57-6.28-5.22-5.1-8.04-13.49
Total Liabilities & Equity
0.240.270.160.350.561.21
Total Debt
1.081.20.790.761.273.58
Net Cash (Debt)
-1.08-1.13-0.79-0.64-1.22-2.86
Net Cash Per Share
-0.02-0.02-0.05-0.04-0.10-0.36
Filing Date Shares Outstanding
108.05108.0510.527.126.716.09
Total Common Shares Outstanding
108.0539.3710.527.016.715.8
Working Capital
-6.57-6.28-5.24-5.18-8.26-13.7
Book Value Per Share
-0.06-0.16-0.50-0.73-1.21-2.33
Tangible Book Value
-6.57-6.28-5.22-5.1-8.08-13.53
Tangible Book Value Per Share
-0.06-0.16-0.50-0.73-1.21-2.33
Source: S&P Global Market Intelligence. Standard template. Financial Sources.